Mesoblast sees little impact from proposed Valeant/Cephalon deal
This article was originally published in Scrip
The Australian regenerative medicine venture Mesoblast expects to weather virtually unscathed the attempt by Valeant Pharmaceuticals to acquire some or all of the assets of Mesoblast's alliance partner, the US speciality pharma firm Cephalon, saying it is protected by plenty of cash on hand and existing agreements.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.